Several other equities research analysts also recently weighed in on HIK. Citigroup boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,250 ($16.18) to GBX 1,475 ($19.09) and gave the stock a buy rating in a research report on Tuesday, May 1st. Numis Securities lowered shares of Hikma Pharmaceuticals to an add rating and upped their price target for the stock from GBX 1,300 ($16.83) to GBX 1,560 ($20.19) in a research note on Friday, May 18th. Peel Hunt reissued a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, April 4th. Finally, Jefferies Financial Group restated a hold rating and set a GBX 997 ($12.91) price target on shares of Hikma Pharmaceuticals in a report on Friday, May 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company’s stock. Hikma Pharmaceuticals currently has an average rating of Hold and an average target price of GBX 1,151.70 ($14.91).
Shares of Hikma Pharmaceuticals traded up GBX 2.50 ($0.03), hitting GBX 1,673 ($21.66), during midday trading on Thursday, MarketBeat.com reports. 658,905 shares of the company’s stock traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($10.54) and a twelve month high of GBX 2,346 ($30.37).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.